An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent for participation before the completion of MT-3995-J05 Study
Completion of MT-3995-J05 study
UACR of ≥300 mg/g Cr with an increase of ≥30% in MT-3995-J05 Study
Symptomatic and clinically significant hypotension
QT prolongation or torsades de pointes
New York Heart Association (NYHA) Class III or IV heart failure
Patients who are judged to be unsuitable for participation based on their safety profile in MT-3995-J05 Study